Biocryst Pharmaceuticals

BCRXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.397 B

$9.38 +0.86%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

$263.9M

#892 by earnings

Shares outstanding

255,535,105

Latest filing cover page

P/E ratio

9.1

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#29Iovance BiotherapeuticsIOVA$2.83B
#30Tarsus PharmaceuticalsTARS$2.79B
#31Biocryst PharmaceuticalsBCRX$2.40B
#32Hemab TherapeuticsCOAG$2.32B
#33VericelVCEL$2.31B

Where these numbers come from

Share counts and financials for Biocryst Pharmaceuticals are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.